Roivant Sciences (ROIV) Operating Expenses (2020 - 2026)

Roivant Sciences (ROIV) has reported Operating Expenses for 7 consecutive years, with $367.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 28.12% year-over-year to $367.8 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (up 11.42% YoY), and the FY2026 full-year result was $1.3 billion, up 13.2% from the prior year.
• Operating Expenses eased to $367.8 million in Q2 2026 per ROIV's latest filing, from $936.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $975.1 million in Q4 2022 and bottomed at $217.5 million in Q3 2023.
• Historically, Operating Expenses has averaged $465.7 million across 5 years, with a median of $307.8 million in 2025.
• The widest YoY moves for Operating Expenses: up 76.8% in 2022, down 58.01% in 2022.
• Over 5 years, Operating Expenses stood at $975.1 million in 2022, then slumped by 31.47% to $668.2 million in 2023, then rose by 27.23% to $850.2 million in 2024, then advanced by 10.1% to $936.0 million in 2025, then tumbled by 60.7% to $367.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $367.8 million, $936.0 million, and $307.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.